Trial Profile
An Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 12 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 08 Apr 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.